Abstract:Regorafenib, an oralmulti-kinaseinhibitor, can inhabit a class of receptor tyrosine kinase, such asangiogenic, stromal, oncogenic and so on. Studies in vitro and clinical trials indicate that regorafenib has significant antitumor activity. The results of clinical trials are encouraging for the treatment of refractory solid tumors, especially for colorectal carcinoma.

Key words:Receptor protein-tyrosine kinases,Enzyme inhibitors,Neoplasms